New paradigms in major depressive disorder
Glutamatergic pathways and the challenges of treatment-resistant depression
Agenda
Learning objective
After attending this webinar, participants should be able to:
- Describe the underlying pathology of the brain in MDD and how this manifests into patient symptoms, with a particular focus of the glutamatergic pathways
- Describe the impact of treatment resistance on patients and the current management strategies for treatment-resistant depression
Faculty:
- Professor Mazda Adli, Germany (TASC) (Chair)
- Professor Ana González-Pinto, Spain (co-chair)
- Professor Siegfried Kasper, Austria
- Professor Christine Denny, USA